Prognostic value of patient-reported outcome thresholds on survival and adverse events in CLL/SLL: A pooled analysis of ibrutinib trials

Citation:

Abuhelwa AY, Almansour SA, Al-Shamsi HO, et al. Ther Adv Hematol. 2026 Aug 28;17:20406207261480380. PMID: 42676539; PMCID: PMC13527353.